

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**


In re Patent Application of

Vassilios PAPADOPOULOS, et al.

Application No. 09/047,652

Filed: March 25, 1998

For: PERIPHERAL-TYPE BENZODIAZEPINE  
RECEPTOR: A TOOL FOR DETECTION,  
DIAGNOSIS, PROGNOSIS, AND  
TREATMENT OF HUMAN BREAST  
CANCER



Group Art Unit: 1642

Examiner: M. Davis

A handwritten signature in black ink, appearing to read "M. Davis" with a date "10/12/00" written below it.

**REPLY AND AMENDMENTS PURSUANT TO 37 C.F.R. §§ 1.111 AND 1.115**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

In response to the Office Action [non-final rejection] mailed on April 12, 2000, kindly amend the above-identified application as follows:

**IN THE CLAIMS:**

Kindly cancel claims 48-52 and substitute the following claims therefor.

--53. An isolated, biologically pure antisense oligonucleotide that possesses a complementary structure to at least a portion of the peripheral-type benzodiazepine receptor (PBR) are having the nucleic acid sequence contained in SEQ ID NO: 1 or SEQ ID NO: 2 wherein said oligonucleotide, when introduced into a cell line that expresses said PBR gene inhibits the expression thereof, and thereby inhibits proliferation of said cell line relative to an otherwise identical cell line which does not comprise said antisense oligonucleotide.

54. The antisense oligonucleotide of claim 53, which possesses a complementary structure to at least a portion of the nucleic acid sequence contained in SEQ ID NO: 1.